NGeneBio Co., Ltd.
Research NGeneBio Co., Ltd. (354200.KQ) on Bullrun: market cap KRW 15.07B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker354200.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 15.07B
- Financial periodQ2 2026
- RevenueKRW 12.45B
- Net income-KRW 3.45B
- Free cash flow-KRW 1.45B
- Gross margin15.3%
Valuation Snapshot
latest market cap is KRW 15.07B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 15.07B | n/a | n/a | n/a |
Dividend history
About NGeneBio Co., Ltd.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NGeneBio Co., Ltd.'s market cap?
NGeneBio Co., Ltd.'s market capitalization is KRW 15.07B.
What does NGeneBio Co., Ltd. do?
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen.